ArticleInflammopharmacology2026
Stigmasterol ameliorates Freund's complete adjuvant-induced polyarthritis in rats.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the anti-arthritic and disease-modifying potential of stigmasterol (STG), a plant-derived bioactive compound, in Freund's Complete Adjuvant (FCA)-induced polyarthritis in rats.
designExperimental arthritis was induced in albino Wistar rats using FCA. The anti-arthritic efficacy of STG was assessed through primary and secondary paw edema, arthritis index, and body-weight changes. Biochemical, haematological, and immunological parameters were evaluated, along with mRNA expression of key mediators using RT-PCR. Histopathological analysis of bone, kidney, and spleen tissues, as well as macroscopic and radiographic joint assessments, was performed. STG was administered orally at doses of 150 and 300 mg/kg and compared with methotrexate (MTX).
resultsFCA induction produced severe arthritic manifestations, including marked paw swelling, an elevated arthritis index, increased rheumatoid factor and anti-cyclic citrullinated peptide levels, and upregulation of inflammatory mediators (TNF-α, NF-κB, IL-1β, IRAK, and IL-17), along with radiographic joint damage and histopathological abnormalities. STG treatment significantly reduced paw edema, improved arthritis severity, and normalized biochemical and haematological parameters in a dose-dependent manner. The higher dose (300 mg/kg) showed efficacy comparable to MTX and significantly enhanced IL-10 expression, indicating restoration of immune balance.
conclusionStigmasterol exhibits potent anti-arthritic, disease-modifying, and organ-protective effects in FCA-induced arthritis, highlighting its therapeutic potential in arthritis management.
Indexed as
Identifiers
41986787What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.